Long title
A Phase 1, Multicenter, Single-arm, Dose--escalation Study of CC 97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS) (CA061-1006)
Date receipt dossier
EudraCT number
2023-507820-22
Company / Sponsor
Celgene
Phase
I
Treated organism
Humans
Indication category
Immune disease
Disease
Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS)
Therapeutic approach
Immunotherapy
Genetic modification
CD19 CAR
Method of transfer of nucleic acid of interest
Lentiviral vector
Route of administration
Intravenous
Locations in Belgium
UZ Gent, UZ Antwerpen
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
CC-97540 (BMS-986353)